Illumina, Inc. announced on February 24, 2025, a series of roadmap innovations, establishing what it describes as the industry's largest portfolio of omics solutions and sequencing applications. These new technologies span genomics, spatial transcriptomics, single-cell analysis, CRISPR technologies, epigenetics, and data analytics software.
The new omics solutions are built on Illumina's sequencers, aiming to surpass industry standards for quality, scale, accuracy, and reliability. Products based on constellation mapped reads technology, designed to streamline whole-genome workflows, are expected to be commercially available in 2026.
The company also detailed its Perturb-seq solution, a single-cell CRISPR research tool expected by the end of 2025, which will offer new kit formats compatible with various cell counts. Additionally, a 5-base insights solution, enabling high-accuracy detection of genetic variants and methylation in a single assay, is planned for launch in 2026, addressing current industry barriers related to cost and usability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.